Report from the CVOT Summit 2020: new cardiovascular and renal outcomes

Cardiovasc Diabetol. 2021 Mar 31;20(1):75. doi: 10.1186/s12933-021-01254-1.


The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 ( ).

Keywords: Cardiovascular disease; Chronic kidney disease; DAPA-CKD; Diabetes; EMPEROR-Reduced; FIDELIO-DKD; GLP-1 receptor agonist; Heart failure; Mineralocorticoid receptor antagonist; Obesity; SGLT2i inhibitor; VERTIS-CV.

Publication types

  • Editorial

MeSH terms

  • COVID-19 / epidemiology*
  • COVID-19 / therapy
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / therapy
  • Clinical Trials as Topic / methods*
  • Congresses as Topic / trends*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / therapy
  • Humans
  • Kidney / drug effects
  • Kidney / physiology
  • Mineralocorticoid Receptor Antagonists / administration & dosage
  • Renal Insufficiency, Chronic / epidemiology*
  • Renal Insufficiency, Chronic / therapy
  • Research Report / trends*
  • Sodium-Glucose Transporter 2 Inhibitors / administration & dosage
  • Treatment Outcome


  • Mineralocorticoid Receptor Antagonists
  • Sodium-Glucose Transporter 2 Inhibitors